ALMOGRAN

This brand name is authorized in Finland, France, Germany, Ireland, Italy, Mexico, Netherlands, Spain.

Active ingredients

The drug ALMOGRAN contains one active pharmaceutical ingredient (API):

1	Almotriptan DL hydrogen malate UNII PJP312605E - ALMOTRIPTAN MALATE
	Almotriptan is a selective 5-HT1B and 5-HT1D receptor agonist. These receptors mediate vasoconstriction of certain cranial vessels, as demonstrated in studies using isolated human tissue preparations.
	Read more about Almotriptan

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ALMOGRAN Film-coated tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N02CC05	Almotriptan	N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CC Selective serotonin (5HT1) agonists
Discover more medicines within N02CC05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00762106, 00762112, 00848606, 00848612, 03104421, 04778305, 06195720, 06195737, 06195743, 06195766, 14241701, 14241718, 17591459, 17604357
ES	Centro de información online de medicamentos de la AEMPS	034996037, 034996037IP, 355614-6, 355614-6IP, 355614-6IP1, 355614-6IP2, 62877
FI	Lääkealan turvallisuus- ja kehittämiskeskus	009083, 015805, 015816, 015827
FR	Base de données publique des médicaments	63564808
IE	Health Products Regulatory Authority	10300, 10352
IT	Agenzia del Farmaco	034996013, 034996037
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	293M2003
NL	Z-Index G-Standaard, PRK	60194